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epidemiology
Primary cutaneous lymphomas (PCLs) are defined as non-
Hodgkin’s lymphomas that present in the skin with no
evidence of extracutaneous disease at the time of diagnosis.
After the gastrointestinal lymphomas, PCLs are the second
most common group of extranodal non-Hodgkin’s
lymphomas with an estimated annual incidence of
1/100 000 in Western countries. PCLs must be distinguished
from nodal or systemic malignant lymphomas involving the
skin secondarily, which often have another clinical
behaviour, have a different prognosis and require a different
therapeutic approach. In recent lymphoma classifications,
PCLs are therefore included as separate entities. Within the
group of PCLs, distinct types of cutaneous T-cell lymphoma
(CTCL) and cutaneous B-cell lymphoma (CBCL) can be
distinguished [1, 2]. In the western world, CTCL constitutes
∼75%–80% of all PCLs, with mycosis fungoides (MF) as the
most common type of CTCL, and CBCL ∼20%–25% [1].
However, different distributions have been observed in other
parts of the world. In southeast Asian countries, CTCLs
other than MF, in particular Epstein-Barr virus-associated
natural killer/T-cell lymphomas, are much more common
than in Western countries, while CBCLs are much more
uncommon [3, 4].
diagnosis
The diagnosis and classification of PCLs should always be based
on a combination of clinical, histological and
immunophenotypical data. Demonstration of clonal T-cell
receptor or immunoglobulin gene rearrangements in lesional
skin or peripheral blood may be a valuable adjunct in selected
cases. However, clinical and histopathological features are, in
most cases, the most important deciding factors for therapeutic
planning. PCLs should be classified according to the criteria of
the World Health Organisation–European Organisation for
Research and Treatment of Cancer (WHO–EORTC)
classification (Table 1) [1].
staging
In all cases, adequate staging should be carried out to exclude
the presence of extracutaneous disease. Staging includes
complete physical examination, complete and differential
blood cell count and serum biochemistry and appropriate
imaging studies (computed tomography scans ± [18F]2-fluoro-
2-deoxy-D-glucose–positron emission tomography scans in all
but stage IA), although they are not required in patients with
lymphomatoid papulosis (LyP) [5, 6]. Flow cytometry of the
peripheral blood should only be carried out in selected cases,
but is mandatory in patients with (suspected) Sézary syndrome
(SS). Bone marrow biopsy and aspiration should be carried out
in cutaneous lymphomas with an intermediate or aggressive
clinical behaviour, but is not required in cutaneous
lymphomas with an indolent clinical behaviour (MF,
cutaneous anaplastic large-cell lymphoma and cutaneous
marginal zone lymphoma), unless indicated by other staging
assessments [5, 6]. The significance of bone marrow
examination in primary cutaneous follicle centre lymphoma
(PCFCL) is controversial [6, 7]. Prognosis is extremely variable
depending on the type of PCL and the stage of disease. For
clinical staging of MF and SS, the revised International Society
for Cutaneous Lymphomas/European Organization of
Research and Treatment of Cancer (ISCL/EORTC) TNMB
(tumour–node–metastasis-blood) staging system should be
used (Tables 2 and 3) [5]. For PCL other than MF/SS, a
separate ISCL/EORTC TNM classification system has been
published [6]. This staging system is primarily intended to
document the extent of disease and cannot be used as a
prognostic guide.
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therapy
The choice of treatment depends on the type of PCL and the
stage of disease. Due to their heterogeneity and rarity, controlled
clinical trials in PCLs are almost non-existent, with a few
exceptions mainly concerning recently marketed drugs.
Recommendations are therefore largely based on (retrospective)
cohort studies and expert opinions discussed during consensus
meetings of the EORTC Cutaneous Lymphoma Group, the
International Society for Cutaneous Lymphomas (ISCL), the
United States Cutaneous Lymphoma Consortium (USCLC) and
the International Lymphoma Radiation Oncology Group.
Consensus recommendations for clinical end points and
response criteria in MF/SS and in PCLs other than MF/SS have
recently been published (Olsen EA, Willemze R, Wood GS et al.
Clinical endpoints and response criteria in primary cutaneous
lymphomas other than mycosis fungoides and Sézary
syndrome: a Consensus Statement of the International Society
for Cutaneous Lymphomas (ISCL), the United States
Cutaneous Lymphoma Consortium (USCLC) and the
Cutaneous Lymphoma Task Force of the European
Organization for the Research and Treatment of Cancer
(EORTC). Blood. In preparation.) [8].
mycosis fungoides and variants
Since early aggressive chemotherapy is associated with
considerable side-effects but does not improve survival, a stage-
adapted conservative therapeutic approach is recommended for
Table 2. Revised TNMB classification of mycosis fungoides (MF) and
Sézary syndrome (SS)
T (skin)
T1 Limited patch/plaque (involving <10% of total skin surface)
T2 Generalised patch/plaque (involving ≥10% of total skin surface)
T3 Tumour(s)
T4 Erythroderma
N (lymph node)
N0 No clinically abnormal peripheral lymph nodes
N1 Clinically abnormal peripheral lymph nodes; histologically
uninvolved
N2 Clinically abnormal peripheral lymph nodes; histologically involved
(nodal architecture uneffaced)
N3 Clinically abnormal peripheral lymph nodes; histologically involved
(nodal architecture (partially) effaced)
Nx Clinically abnormal peripheral lymph nodes; no histological
confirmation
M (viscera)
M0 No visceral involvement
M1 Visceral involvement
B (blood)
B0 No circulating atypical (Sézary) cells (or <5% of lymphocytes)
B1 Low blood tumour burden (≥5% of lymphocytes are Sézary cells,
but not B2)
B2 High blood tumour burden (≥1000/µl Sézary cells and positive
clone)
Republished with permission of American Society of Hematology, from
Olsen E, Vonderheid E, Pimpinelli N et al., Revisions to the staging and
classification of mycosis fungoides and Sézary syndrome: a proposal of the
International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous
Lymphoma Task Force of the European Organization of Research and
Treatment of Cancer (EORTC), Blood 2007; 110: 1713–1722; permission
conveyed through Copyright Clearance Center, Inc.
Table 1. World Health Organisation–European Organisation for
Research and Treatment of Cancer (WHO–EORTC) classification
Cutaneous T-cell lymphoma (CTCL)
Mycosis fungoides (MF)
Variants of MF
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Sézary syndrome (SS)
Primary cutaneous CD30-positive lymphoproliferative disorders
Primary cutaneous anaplastic large-cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal natural killer (NK)/T-cell lymphoma, nasal-type
Primary cutaneous peripheral T-cell lymphoma-not otherwise specified
Aggressive epidermotropic CD8+ CTCLa
Cutaneous γ/δ T-cell lymphomaa
CD4+ small/medium-sized pleomorphic CTCLa
Cutaneous B-cell lymphoma (CBCL)
Primary cutaneous marginal zone B-cell lymphoma
Primary cutaneous follicle centre lymphoma
Primary cutaneous diffuse large B-cell lymphoma, leg type
aProvisional entities.
Republished with permission of the American Society of Hematology,
from Willemze R, Jaffe ES, Burg G et al., WHO/EORTC classification
for cutaneous lymphomas Blood 2005; 105: 3768–3785; permission
conveyed through Copyright Clearance Center, Inc.
Table 3. Revised clinical staging system for mycosis fungoides (MF) and
Sézary syndrome (SS)
Clinical stage
IA T1 N0 M0 B0-1
IB T2 N0 M0 B0-1
IIA T1–2 N1-2 M0 B0-1
IIB T3 N0-2 M0 B0-1
III T4 N0-2 M0 B0-1
IVA1 T1-4 N0-2 M0 B2
IVA2 T1-4 N3 M0 B0-2
IVB T1-4 N0-3 M1 B0-2
Republished with permission of American Society of Hematology, from
Olsen E, Vonderheid E, Pimpinelli N et al., Revisions to the staging and
classification of mycosis fungoides and Sézary syndrome: a proposal of the
International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous
Lymphoma Task Force of the European Organization of Research and
Treatment of Cancer (EORTC), Blood 2007; 110: 1713–1722; permission
conveyed through Copyright Clearance Center, Inc.
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MF and its variants [9–12]. Patients with only patches and/or
plaques covering <10% (stage IA) or ≥10% of the skin surface
(stage IB) should be treated with skin-directed therapies,
including topical steroids, psoralens + ultraviolet A (PUVA),
narrow-band ultraviolet B (UVB) and topical cytostatic agents,
such as mechlorethamine or carmustine (BCNU). Narrow-band
UVB should only be used in patients with patches or very thin
plaques. Topical steroids can be recommended as monotherapy
for patches/flat plaques stage IA disease. In stage IB, topical
steroids can be used as adjuvant therapy for selected skin
lesions. In patients developing one or few infiltrated plaques or
tumours (stage IIB), additional local radiotherapy may suffice.
Local radiotherapy can be curative in patients with early
localised disease, particularly in patients with unilesional MF
and pagetoid reticulosis. Local radiotherapy is most commonly
administered with electrons (energy dependent on the thickness
of the lesion), with bolus to achieve full skin dose, a margin of
≥2 cm and a total dose of 24–36 Gy. For patients with more
extensive infiltrated plaques and tumours or patients refractory
to skin-directed therapies, a combination of PUVA and
interferon alpha or PUVA and retinoids (including bexarotene),
a combination of interferon alpha and retinoids or total skin
electron beam irradiation can be considered. However, these
treatments are not curative, although remission may last for
several years. Total skin electron beam irradiation was often
given to total doses of 30–36 Gy, but recently lower doses
(10–12 Gy) have been employed with the advantages of shorter
duration of the treatment period, fewer side-effects and
opportunity for re-treatment [13]. In patients with advanced
and refractory disease, gemcitabine or liposomal doxorubicin
may be considered [14, 15]. Other agents like the fusion toxin
denileukin diftitox and histone deacetylase (HDAC) inhibitors,
such as vorinostat and romidepsin, have been approved in the
United States by the Food and Drug Administration (FDA) for
patients with relapsed and refractory CTCL, but have not yet
been registered for CTCL in Europe [16–18]. Multiagent
chemotherapy is only indicated in patients with effaced lymph
nodes or visceral involvement (stage IV), or in patients with
widespread tumour stage MF which cannot be controlled with
skin-targeted and immunomodulating therapies. Local
palliation of cutaneous as well as extracutaneous lesions may be
achieved with local radiotherapy to doses ≥8 Gy [19]. In
relatively young patients with refractory, progressive MF or with
SS, allogeneic stem cell transplantation may be considered.
Durable responses have been reported, but experience is still
limited, and the optimal conditioning regimen and the optimal
timing for an allogeneic transplant are currently unknown [20].
Results with autologous stem cell transplantation in MF and SS
have been disappointing.
Sézary syndrome
Being a systemic disease (i.e. leukaemia) by definition, systemic
treatment is required. Skin-directed therapies like PUVA or
potent topical steroids may be used as adjuvant therapy.
Extracorporeal photopheresis (ECP), either alone or in
combination with other treatment modalities such as interferon
alpha, retinoids, total skin electron beam and PUVA, has been
suggested as the treatment of choice in SS and erythrodermic
MF [10–12]. Overall response rates range from 30% to 80% with
complete response rates ranging from 14% to 25%, depending
on the ECP regimen and the type of combination used.
However, the suggested superiority of ECP over the traditional
low-dose chemotherapy regimens has not yet been substantiated
by randomised, controlled trials [21]. Prolonged treatment with
a combination of low-dose chlorambucil and prednisone is
often effective in controlling the disease, but is unlikely to yield
complete responses. Low-dose methotrexate, bexarotene,
denileukin diftitox, alemtuzumab (low-dose) and multiagent
chemotherapy have been recommended as second-line
treatment of SS [10–12, 22]. It should be emphasised that
comparison of treatment results in the different studies is almost
impossible due to differences in diagnostic criteria used for SS.
primary cutaneous CD30-positive
lymphoproliferative disorders (LPDs)
The group of primary cutaneous CD30-positive LPDs includes
primary cutaneous anaplastic large lymphoma (C-ALCL) and
LyP, which form a spectrum of disease. Both C-ALCL and LyP
have an excellent prognosis, with a 10-year survival of 90% and
almost 100%, respectively [23, 24]. Patients with C-ALCL
generally present with solitary or localised (ulcerating) tumours
or nodules and should be treated with radiotherapy or surgical
excision. Patients with C-ALCL presenting with multifocal skin
lesions can be best treated with low-dose methotrexate, as in
LyP, or radiotherapy in case of only a few lesions. Radiotherapy
is commonly administered with electrons, with bolus, a margin
of ≥2 cm and a total dose of 40 Gy [25]. This dose is effective
and well-tolerated. Lower doses may achieve the same result, but
data have not been published. In patients with multiple lesions,
lower doses of radiation may be used for palliation. In cases not
responsive to these treatments, systemic retinoids including
bexarotene or interferon alpha can be used [24]. Recent
preliminary studies report high response rates of brentuximab
vedotin (anti-CD30 monoclonal antibody coupled to the anti-
tubulin agent monomethyl auristatin E) in patients with C-
ALCL as well as patients with MF expressing CD30, but
controlled clinical trials have just started [26, 27]. Multiagent
chemotherapy is only indicated in patients presenting with or
developing extracutaneous disease and in rare patients with
rapidly progressive skin disease.
subcutaneous panniculitis-like T-cell
lymphoma (SPTCL)
The term SPTCL is only used for cases with an α/β T-cell
phenotype, which have a favourable prognosis, particularly if
not associated with a haemophagocytic syndrome (HPS), which
is frequently an extremely aggressive clinical syndrome
requiring immediate intervention. One study reported 5-year
overall survival rates of 91% and 46% in SPTCL patients without
and with an HPS, respectively [28]. In SPTCL without
associated HPS, systemic steroids or other immunosuppressive
agents should be considered first, whereas in cases of solitary or
localised skin lesions, radiotherapy with electrons is advised.
Annals of Oncology clinical practice guidelines
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Little information on radiation dose is available, but a dose of
40 Gy has been used. Bexarotene may be also effective in SPTCL
[29]. Multiagent chemotherapy is required only in cases with
progressive disease not responding to immunosuppressive
therapy or in cases with HPS.
extranodal natural killer (NK)/T-cell
lymphoma, nasal type
Extranodal NK/T-cell lymphoma, nasal type is a rare, nearly
always Epstein-Barr virus-positive lymphoma, which is more
common in Asia and Central and South America. The skin is
the second most common site of involvement after the nasal
cavity/nasopharynx. Patients generally present with multiple
(ulcerating) plaques and tumours, or in the case of nasal
NK/T-cell lymphoma with a midfacial destructive tumour. Skin
involvement may be a primary or secondary manifestation of
the disease. One study reported a median survival of 27 months
for patients presenting with only skin lesions, compared with
5 months for patients presenting with cutaneous and
extracutaneous diseases [30]. Since both groups have an
aggressive clinical behaviour, distinction between primary and
secondary cutaneous involvement seems not to be useful for
this category. In patients with stage I disease, radiotherapy is the
first choice of treatment. Recommended radiation doses are
higher than for other lymphomas, with 50 Gy to the initial
lesion and a boost of 5–10 Gy to residual disease. In the case of
more advanced disease, these lymphomas show an aggressive
clinical behaviour and are often resistant to chemotherapy.
Recently, an intensive chemotherapy regimen including
L-asparaginase (the SMILE regimen) was shown to be
effective [31].
primary cutaneous peripheral T-cell
lymphoma-not otherwise specified
(PTCL-NOS)
Within the group of primary cutaneous PTCL-NOS, three
somewhat better defined subgroups have been included as
provisional entities (see Table 1). However, most of the cases
have in common a generally aggressive clinical course and poor
survival, and should therefore be treated as systemic PTCL-NOS
with multiagent chemotherapy. Since the results are often
disappointing, early allogeneic stem cell transplantation may be
considered. The only exception is the group of CD4-positive
small-medium pleomorphic CTCL. These patients often present
with a solitary tumour, most commonly on the head, should be
treated with local radiotherapy or excision, and have an
excellent prognosis.
cutaneous B-cell lymphoma
In the WHO–EORTC classification, three main types of CBCL
are distinguished: primary cutaneous marginal zone lymphoma
Table 4. Recommendations for the initial management of CBCL
Extent First-line therapy Alternative therapies
PCMZL Solitary/localised Local radiotherapy
Excision
(Antibiotics)a
IFN alpha i.l.
Rituximab i.l.
Intralesional steroids
Multifocal Wait and see
Local radiotherapy
Chlorambucilb
Rituximab i.v.
(Antibiotics)a
IFN alpha i.l.
Rituximab i.l.
Topical or intralesional steroids
PCFCL Solitary/localised Local radiotherapy
Excision
IFN alpha i.l.
Rituximab i.l.
Multifocal Wait and see
Local radiotherapy
Rituximab i.v.
R-CVP/CHOPc
PCLBCL, LT Solitary/localised R-CHOP ± IFRT Local radiotherapy
Rituximab i.v.
Multifocal R-CHOP Rituximab i.v.
aIn case of evidence for Borrelia burgdorferi infection,
bor other single or combination regimens appropriate for low-grade B-cell lymphomas,
cin exceptional cases or for patients developing extracutaneous disease i.l. intralesional; i.v.: intravenous; IFRT: involved field radiotherapy.
Republished with permission of American Society of Hematology, from Senff NJ, Noordijk EM, Kim YH et al., European Organization for Research and
Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas,
Blood 2008; 112: 1600–1609; permission conveyed through Copyright Clearance Center, Inc.
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(PCMZL), PCFCL and primary cutaneous diffuse large B-cell
lymphoma, leg type (PCLBCL-LT). PCMZL and PCFCL are
indolent types of CBCL with a disease-related 10-year survival
rate of 90%, while PCLBCL-LT has a more unfavourable
prognosis (disease-related 5-year survival, ∼50%). EORTC/ISCL
consensus recommendations for the management of these three
types of CBCL have been formulated and are summarised in
Table 4 [32]. Recommended radiation doses for localised
PCMZL and PCFCL are 24–36 Gy, whereas for palliative
treatment of multifocal disease, low-dose radiation (4 Gy) is
often sufficient [19]. For the more aggressive PCLBCL-LT, a
radiation dose of 40 Gy is recommended.
personalised medicine
In this disease setting, more research is needed to identify
molecular markers which could lead to advances in
personalised medicine.
follow-up
The frequency of follow-up visits depends on the type of PCL
and the stage of disease. It may vary from every 6 or 12 months
in patients with indolent types of PCL and stable disease or
patients in complete remission to every 4–6 weeks in patients
with active or progressive disease. Follow-up visits should focus
on history and physical examination, and additional testing
(histology, blood examination, imaging, etc.) should only be
carried out if required.
note
According to the levels of evidence and grades of
recommendation shown in Table 5, the levels of evidence in
these guidelines are mostly level IV and the recommendations
are grade B. This is due to the heterogeneity and rarity of the
diseases.
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